Remicade props up Mitsubishi Tanabe in weak first quarter
This article was originally published in Scrip
Executive Summary
Prescription pharmaceutical sales at Mitsubishi Tanabe Pharma (MTP) in Japan dipped by 2% to ¥98.2 billion ($1.03 billion) in the first quarter to June 30th despite strong Japanese growth for Remicade.